600216 Zhejiang Medicine
- 9.62
- +0.07+0.73%
Zhejiang Medicine News
China Grants Clinical Trial Approval for Zhejiang Medicine's Antibacterial Injection
China's medical products administrator granted clinical trial approval to Zhejiang Medicine's (SHA:600216) LYSC98 injectable antibacterial drug indicated for common clinical gram-positive bacteria, ac
Zhejiang Medicine (SHSE:600216) Takes On Some Risk With Its Use Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company is, we always like to look at its use of debt, since debt overload can lead to rui
Zhejiang Pharmaceutical (600216.SH): No plans to develop or sell weight loss drugs
Gelonghui, May 10 丨 Zhejiang Pharmaceutical (600216.SH) said on the investor interactive platform that the company currently has no plans to develop or sell weight loss drugs.
Zhejiang Pharmaceutical (600216.SH): Net profit of 110 million yuan in the first quarter decreased by 3.44% year on year
On April 25, Ge Longhui (600216.SH) released its first quarter report. Operating revenue was 2,249 million yuan, up 12.01% year on year, net profit of 110 million yuan, down 3.44% year on year, after deducting non-net profit of 106 million yuan, up 8.07% year on year, with basic earnings per share of 0.11 yuan.
Zhejiang Pharmaceutical (600216.SH): Currently, the company's NMN products are only exported and sold to some overseas countries or regions that allow the product to be sold as a health product
Gelonghui, March 29丨Zhejiang Pharmaceutical (600216.SH) said on the investor interactive platform that NMN products cannot be registered and sold as pharmaceuticals or health products under current domestic regulations. Currently, the company's NMN products are only exported and sold to some overseas countries or regions that allow the product to be sold as health products. This business is an export/cross-border business being cultivated by the company's health products sector, and sales volume in 2023 will not be significant.
Zhejiang Medicine Co., Ltd.'s (SHSE:600216) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Zhejiang Medicine (SHSE:600216) has had a rough three months with its share price down 16%. But if you pay close attention, you might find that its key financial indicators look quite decent, which
The Three-year Shareholder Returns and Company Earnings Persist Lower as Zhejiang Medicine (SHSE:600216) Stock Falls a Further 4.0% in Past Week
For many investors, the main point of stock picking is to generate higher returns than the overall market. But if you try your hand at stock picking, your risk returning less than the market. We reg
Zhejiang Medicine Co., Ltd. (SHSE:600216) Doing What It Can To Lift Shares
With a price-to-earnings (or "P/E") ratio of 24.3x Zhejiang Medicine Co., Ltd. (SHSE:600216) may be sending bullish signals at the moment, given that almost half of all companies in China have P/E rat
Zhejiang Pharmaceutical (600216.SH): Accredited as a high-tech enterprise
Gelonghui, January 11, Zhejiang Pharmaceutical (600216.SH) announced that the company received the “High-tech Enterprise Certificate” jointly approved and issued by the Zhejiang Provincial Department of Science and Technology, the Zhejiang Provincial Department of Finance, and the Zhejiang Provincial Taxation Bureau of the State Administration of Taxation. Certificate number: GR202333011136, date of issue: December 8, 2023, valid for three years. This is a re-certification carried out after the expiration of the company's original high-tech enterprise certificate.
Zhejiang Medicine (SHSE:600216) Has A Somewhat Strained Balance Sheet
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' When we think about how
Zhejiang Pharmaceutical (600216.SH): The company produces and sells miglitol APIs
Glonghui, December 18|Zhejiang Pharmaceutical (600216.SH) stated on the investor interactive platform that the company produces and sells miglitol APIs.
Zhongxin Fluorine (002915.SZ): Pharmaceutical intermediates are mainly supplied to pharmaceutical companies such as Guobang Pharmaceutical, Jingxin Pharmaceutical, Zhejiang Pharmaceutical, and Proluo Pharmaceutical
Gelonghui December 18丨Zhongxin Fluorine Materials (002915.SZ) stated on the investor interactive platform that the company's pharmaceutical intermediates are mainly supplied to pharmaceutical companies such as Guobang Pharmaceutical, Jingxin Pharmaceutical, Zhejiang Pharmaceutical, and Proluo Pharmaceutical.
Zhejiang Pharmaceutical (600216.SH): The company's levofloxacin formulation products include injections and tablets
Gelonghui November 30丨Zhejiang Pharmaceutical (600216.SH) said on an interactive platform that the company's levofloxacin formulation products include injections and tablets. The priority of levofloxacin and nanofloxacin malate in the clinical use of Chlamydia mycoplasma pneumonia depends on the specific clinical situation and the physician's comprehensive judgment.
Zhejiang Pharmaceutical (600216.SH): The indications of some antibiotic products produced include respiratory diseases in some cases of infection
Gelonghui November 30丨Zhejiang Pharmaceutical (600216.SH) said on an interactive platform that there are many causes of respiratory diseases, and the indications of some antibiotic products produced by the company include respiratory diseases in some cases of infection. Please note that the company's antibiotic products are all prescription drugs and should be used under the guidance of a physician.
Zhejiang Pharmaceutical (600216.SH): Does not produce azithromycin APIs or preparations
Gelonghui, November 30|Zhejiang Pharmaceutical (600216.SH) said on an interactive platform that the company does not produce azithromycin APIs or preparations.
Zhejiang Medicine Wins Nod to Trial Digestive Acid Drug
Zhejiang Medicine (SHA:600216) has obtained approval from China's National Medical Products Administration to carry out a clinical trial of its drug candidate for the treatment of acid-related disease
Zhejiang Medicine Co., Ltd.'s (SHSE:600216) Stock Has Shown A Decent Performance: Have Financials A Role To Play?
Most readers would already know that Zhejiang Medicine's (SHSE:600216) stock increased by 8.2% over the past three months. We wonder if and what role the company's financials play in that price chan
Zhejiang Medicine (600216.SH): Currently there are no drugs indicated for Alzheimer's disease
Gelonghui November 17丨Zhejiang Pharmaceutical (600216.SH) said on an interactive platform that the company currently has no drug indications for Almerzheimer's disease. If the progress of the innovative chemical drug and biomacromolecule innovative drug projects being developed by the company falls into the disclosure obligation, the company will promptly disclose it on the official website of the Shanghai Stock Exchange.
Zhejiang Pharmaceutical (600216.SH): The US export business of vancomycin hydrochloride has begun to be commercialized this year
Gelonghui November 17丨Zhejiang Pharmaceutical (600216.SH) said on an interactive platform that the company's vancomycin hydrochloride formulation export business to the US has begun commercialization this year and generated revenue in the third quarter of this year.
[Instant Analysis of BT Financial Report] Zhejiang Pharmaceutical 2023 Third Quarter Report: Sales of life nutrition products declined, net cash flow increased significantly
Announcement time of this financial report: 2023-10-25 17:37:01 Zhejiang Pharmaceutical (stock code: 600216) is a pharmaceutical manufacturing company listed on the Shanghai Stock Exchange. Its main business includes life nutrition products, pharmaceutical manufacturing products, and pharmaceutical business. Its strict procurement model and diversified main business have given it a place in the pharmaceutical industry. Judging from the financial situation, Zhejiang Pharmaceutical's total assets for the third quarter of 2023 were 12.593 billion yuan, up from 12.433 billion yuan at the end of the previous year. Total liabilities were $2,694 million, slightly lower than at the end of the previous year
Analysis
Price Target
No Data
